Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

NCT04572841 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Sjögren's Syndrome
Sjogren's Syndrome

Interventions

DRUG: SAR441344
DRUG: Placebo

Sponsor

Sanofi